Expanding Valve Repair in Rheumatic Heart Disease

Ahmed Afifi (*), Nairouz Shehata 1, Mohamed Nagi 1, Abdel Rahman Sultan 1 and Magdi Yacoub 1,2

1 Magdi Yacoub Heart Foundation-Aswan Heart Centre, Cairo, Egypt, 2 Department of Biomedical Engineering, Imperial College London, London, United Kingdom

Rheumatic heart disease is a serious ailment with significant morbidity and mortality in endemic areas; yet, there is no agreement on indication, timing, and surgical modality for treating rheumatic valve affection. There is mounting evidence that rheumatic mitral valve repair is possible with good long-term results, less is the case with rheumatic aortic valve disease. We discuss the surgical approach for both valves emphasizing the role of multimodality imaging.

Keywords: rheumatic mitral repair, rheumatic aortic repair, rheumatic valve imaging, rheumatic valve disease, rheumatic valve surgery

INTRODUCTION

Affecting >1% of the population in endemic countries, rheumatic heart valve disease is responsible for the death of over 300,000 patients every year (1). Rheumatic valve disease most commonly affects the mitral valve, although around 30% of cases have aortic valve affection causing varying degrees of aortic stenosis (in 9%), regurgitation (14%), or both (6%) (2). It is a progressive disease that continues to evolve well into adulthood. There is still no agreement about the best method for treating rheumatic valve disease, with the debate of repair vs. replacement continuing.

Repair has many advantages; however, it also has its limitations and shortcomings. In this article, we review our recent developments toward perfecting the results of rheumatic valve repair with particular emphasis on the role of multimodality imaging.

TIMING AND INDICATION

The timing of surgery in the setting of rheumatic valve disease is a topic that has not been fully addressed. Currently, the guidelines for non-rheumatic valve disease are being used to guide timing (3). Recent evidence supports rather early intervention, before the setting of irreversible myocardial damage, especially in young patients with a long, expected survival (4). It could also be added that early valve intervention, before the development of more severe rheumatic changes in the valves, could improve the likelihood of surgical repair.

REPAIR VS. REPLACEMENT

Mechanical valve replacement has long been considered the classical surgical treatment for rheumatic valve disease (5). Its results are reliable in the short term with low mortality and rarely any postoperative incidence of stenosis or regurgitation. The long-term results, however, have remained far from optimal because of increased risk of thromboembolism and bleeding, both of which are further compounded by limited access to medical follow-up and anticoagulation supply (2, 6). Bioprostheses offer a lower risk of bleeding and thromboembolism but has been shown to
expanding repairs in rhd degenerate very quickly in young patients (5) notwithstanding the detrimental effects of prosthetic valve replacement on ventricular function, quality of life, and survival. it is, therefore, apparent that reliable valve repair would be preferred in this young population.

the mitral and tricuspid valves

although more difficult than in degenerative mitral valve disease, rheumatic mitral valve repair is certainly possible with good outcomes, both in the short and long term, especially in young patients with isolated mitral regurgitation or stenosis (7–9). older patients, those with mixed mitral valve pathology and calcified or diffusely thick, amalgamated valves, have generally shown less satisfying results (9). repairing the rheumatic mitral valve, however, requires a thorough understanding of the pathophysiology of rheumatic valve disease and the dynamics of mitral valve motion during the cardiac cycle, bearing in mind that rheumatic mitral repair is unique in that it requires ensuring unobstructed flow of blood from the atrium to the ventricle, a diastolic phenomenon, not just correcting the incompetence that occurs in systole (8, 10).

rheumatic mitral regurgitation presents with a thin but short anterior mitral leaflet, a tethered posterior leaflet, thin elongated cords, and a dilated annulus. it is treated by following the carpentier steps of functional segmental analysis and repair, treating the cause of incompetence, achieving a good surface of coaptation, and stabilizing the annulus (11). we have achieved this using techniques like peeling the leaflets to improve length and pliability, shortening or replacement of cords, and limiting triangular resections, or free edge application of the anterior mitral leaflet, release of secondary cords, and release of the papillary muscles from the ventricle wall and from each other. annular stabilization and/or reduction is only achieved by a flexible posterior annuloplasty band (figure 1).

rheumatic mitral valve stenosis presents with varying degrees of leaflet and sub-valvular thickening, fibrosis, and calcification. the commissures are usually fused, and the annulus is rarely dilated and usually fibrotic (7). this more difficult pathology is treated by extended commissurotomy, cutting of the fused commissures in the correct plane where both sides are supported by cords, in addition, to release the commissural cords as well as the underlying papillary muscles to further enhance the opening of the valve. when the mitral leaflets are thickened, extensive peeling of the rheumatic membrane causes tangible improvement in leaflet thickness, pliability, and length. peeling is started at the annular edge of the leaflet using a plane formed by the exit sites of the annuloplasty sutures and followed with blunt dissection till the leaflet free edge. sharp dissection with scissors or a scalpel blade is usually necessary on the coapting surface of leaflets where the rheumatic membrane is more adherent. all thick cords are dealt by thinning, fenestration, wedge resection, or replacement. this step is particularly important in easing the diastolic opening of the valve and reducing gradient, as the diastolic inflow into the lv is an active process that requires restoration at all levels of the mitral apparatus (8). in majority of patients with isolated mitral stenosis, annuloplasty is not required.

in many patients, there is secondary tricuspid valve regurgitation, which requires treatment during operation. not uncommonly, there is an associated primary rheumatic pathology in the tricuspid valve, causing thickening, fibrosis, and shortening of leaflets and cords. commissural fusion could sometimes be found, causing tricuspid stenosis, which

![Figure 1](https://example.com/figure1.png)
should be dealt with by commissurotomy that is usually more straightforward than that of the mitral valve. We have a low threshold for performing tricuspid valve annuloplasty, a practice that has recently been validated by a randomized trial (12).

**THE AORTIC VALVE**

Repairing the rheumatic aortic valve poses a surgical challenge. This is due to the nature of rheumatic disease, causing stiffening and shrinkage of the leaflets, which does not leave much tissue for repair (13, 14). The most readily repairable valves are those with mild to moderate stenosis or regurgitation in patients who are admitted for the repair of mitral pathology. These are corrected by sharp dissection of commissures with a scalpel and accompanied by blunt dissection to peel the rheumatic membrane from the ventricular surface of the cusps (Figure 1). This technique could be effective in both moderate aortic stenosis and regurgitation, as it leads to improved length and mobility of the leaflets (15).

In more severe cases of aortic stenosis, the previous technique could be accompanied by focal decalcification and shaving of the free edge of the leaflets. This, however, has not yielded better long-term results than aortic valve replacement with bioprosthesis, and even short-term freedom from mild to moderate aortic stenosis is not guaranteed, as residual aortic stenosis usually results from the stiff leaflets (15). Removal of the cusps and implantation of autologous pericardial leaflets with high commissural suspension (Ozaki technique) has shown very good mid-term results, but it should be considered as stent-less aortic valve replacement rather than repair (16).

Augmentation of the aortic leaflets with pericardium is also beneficial in cases with rheumatic aortic regurgitation. We prefer incising the belly of the cusps and adding a lozenge-shaped pericardial patch that would result in a larger leaflet size and a free edge of native aortic tissue. This, in our hands, has yielded better results than augmenting the cusp-free edge with a ribbon of the pericardium (15). For all the above techniques, the use of pericardium, fresh or treated, has not been optimal, neither the use of other materials, like PTFE or extracellular matrix (16–18). The use of tissue-engineered patches with optimal shape and material will expectantly be beneficial in the future for reconstruction or replacement of valve leaflets (19). For irreparable aortic valves, pulmonary autograft implantation, the Ross operation, remains the best surgical treatment modality that offers superior survival and quality of life advantage (20).

**THE ESSENTIAL ROLE OF MULTIMODALITY IMAGING**

Assessment of the suitability of the aortic valve for repair, guiding the type of valve conserving procedure, and importantly determining the early and long-term efficacy of the intervention...
depends on defining valve structure and function. This is achieved by the combination of multimodality imaging and a variety of computerized image analysis techniques. The available imaging modalities include 2- and 3-dimensional echocardiography, continuous flow Doppler, multi-slice CT, and cardiac magnetic resonance (CMR). Image analysis aims at defining the size, shape, thickness, and mobility of each component of the valve, degree of leaflet coaptation, and kinematics of the leaflets and annulus. In addition, ventriculo-arterial coupling, energy loss, and pattern of flow-through and distal to the valve are determined (Figure 2).

A novel combination of CT segmentation and four-dimensional (4D) echocardiography mesh segmentation to determine the morphodynamics of the mitral valve could provide the ideal method of assessing the functional anatomy of the valve. Studying these parameters helps in optimizing surgical techniques toward a personalized approach. Importantly, MRI-determined 4D imaging plays a major role in planning a surgical technique to maintain LV function (Figure 2) (21). This supports the concept of applying the concept of maintaining morphodynamics in cardiac surgery (22, 23).

CONCLUSIONS AND FUTURE DIRECTION

Techniques continue to evolve, but as it currently stands, there is no perfect repair for rheumatic valve disease. In a young and physically active population with limited access to medical care, it is important to try hard to avoid replacing these valves even if it is just a temporizing solution (24). A tailored approach to rheumatic valve disease should be followed based on patient profile and cardiac condition, with the aid of multimodality imaging (8). Equally important is to identify which valves are not suitable for reasonable valve repair, be it due to extent of valve pathology, overall cardiac condition, or patient profile.

There is a pressing need for specialized centers for the treatment of rheumatic heart valve disease where hospitals and surgeons, and volume of cases would increase the likelihood of a successful, durable, and, importantly, reproducible repair (25, 26). It is also critical to enhance facilities for postoperative follow-up of patients in terms of medical treatment, anticoagulation, ventricular function, and, importantly, quality of life.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/ supplemental material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

AA and MY contributing to the intellectual and writing components as well as the surgical details and figures. NS, MN, and AS contributed to intellectual and writing components of the multimodality imaging section of the manuscript in addition to the relevant figures. MG guiding the intellectual direction of the manuscript, revising, and editing all sections of the work. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhmun G, et al. Global, regional, and national burden of rheumatic heart disease, 1990–2015. N Engl J Med. (2017) 377:713–22. doi: 10.1056/NEJMoA1603693

2. Yacoub M, Mayosi B, ElGuindy A, Carpentier A, Yusuf S. Eliminating acute rheumatic fever and rheumatic heart disease. Lancet. (2017) 390:212–3. doi: 10.1016/S0140-6736(17)31608-2

3. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. (2017) 135:e1159–e1195. doi: 10.1161/CIR.0000000000000503

4. d’Udekem Y, Sharma V. Repair Options in Rheumatic Aortic Valve Disease in Young Patients. World J PediatrCongenit Heart Surg. (2013) 4:392–6. doi: 10.1177/215013513496440

5. Choudhary SK, Talwar S, Airan B. Choice of prosthetic heart valve in a developing country. Heart Asia. (2016) 8:65–72. doi: 10.1136/heartasia-2015-010650

6. Watkins DA, Beaton AZ, Carapetis JR, Karthikeyan G, Mayosi BM, Wyber R, et al. Rheumatic heart disease worldwide. J Am Coll Cardiol. (2018) 72:1397–416. doi: 10.1016/j.jacc.2018.06.063

7. Chotivatanapong T, Lersdsomboon P, Sungkhapong V. Complex surgical repair of rheumatic mitral stenosis. Ann Cardiothorac Surg. (2015) 4:480–2. doi: 10.3978/j.issn.2225-319X.2015.03.06

8. Yacoub MH, Cohn LH. Novel approaches to cardiac valve repair: from structure to function: Part I. Circulation. (2004) 109:942–50. doi: 10.1161/01.CIR.0000115633.19829.5E

9. Antunes MJ. Challenges in rheumatic valvular disease: Surgical strategies for mitral valve preservation. Glob Cardiol Sci Pract. (2015) 2015:9. doi: 10.5339/gcsp.2015.9

10. Yacoub MH, Kilner PJ, Birks EI, Misfield M. The aortic outflow and root: a tale of dynamism and crosstalk. Ann Thorac Surg. (1999) 68:837–43. doi: 10.1016/S0003-4975(99)00745-6

11. Carpentier A. Cardiac valve surgerythe “French correction”. J Thorac Cardiovasc Surg. (1983) 86:323–37. doi: 10.1016/S0022-5223(19)39144-5

12. Gammie J, Chu M, Fink V, Overby J, Moskowitz A, Gillinov M, et al. Concomitant tricuspid repair in patients with degenerative mitral regurgitation. N Engl J Med. (2022) 386:327–39. doi: 10.1056/NEJMoa2115961

13. Talwar S, Saikrishna C, Saxena A, Kumar AS. Aortic valve repair for rheumatic aortic valve disease. Ann Thorac Surg. (2005) 79:1921–5. doi: 10.1016/j.athoracsur.2004.11.042

14. Carabello BA. Assessment of the patient with valvular heart disease: An integrative approach. Aswan Hear Cent Sci Pract Ser. (2011) 2011:15. doi: 10.5339/ahcsps.2011.15

15. Afifi A, Hosny H, Yacoub M. Rheumatic aortic valve disease—when and who to repair? Ann Cardiothorac Surg. (2019) 8:383–9. doi: 10.21037/acs.2019.05.01

16. Ozaki S, Kawase I, Yamashita H, Uchida S, Takatoh M, Kiyohara N. Midterm outcome after aortic valve neocuspization with glutaraldehydethreated autologous pericardium. J Thorac Cardiovasc Surg. (2018) 155:2379–87. doi: 10.1016/j.jtcvs.2018.01.087
17. Nosál’ M, Poruban R, Valentík P, Šagát M, Nagi AS, Kántorová A. Initial experience with polytetrafluoroethylene leaflet extensions for aortic valve repair. *Eur J Cardiothorac Surg*. (2012) 41:1255–7. doi: 10.1093/ejcts/ezt214

18. Przybylski R, Pawlak S, Sliwka J, Urlik M, Maruszewski M, Kukulski T et al. Aortic cusp extension valvuloplasty: repair with an extracellular patch. *Kardiochir Torakochirurgia Pol*. (2015) 12:314–7. doi: 10.5114/ktp.2015.56780

19. Yacoub MH. In search of living valve substitutes. *J Am Coll Cardiol*. (2015) 66:889–91. doi: 10.1016/j.jacc.2015.07.007

20. El-Hamamsy I, Eryigit Z, Stevens LM, Sarang Z, George R, Clark L, et al. Long-term outcomes after autograft versus homograft aortic root replacement in adults with aortic valve disease: a randomised controlled trial. *Lancet*. (2010) 376:524–31. doi: 10.1016/S0140-6736(10)60828-8

21. Elbaz MSM, Calkoen E, Westenberg J, Lelieveldt B, Roest A, van der Geest R. Vortex flow during early and late left ventricular filling in normal subjects: Quantitative characterization using retrospectively-gated 4D flow cardiovascular magnetic resonance and three-dimensional vortex core analysis. *J Cardiovasc Magn Reson*. (2014) 16:78. doi: 10.1186/s12968-014-0078-9

22. Kilner PJ, Yang GZ, Wilkes AJ, Mohiaddin RH, Firmin DN, Yacoub MH. Asymmetric redirection of flow through the heart. *Nature*. (2000) 404:759–61. doi: 10.1038/35008073

23. Yacoub MH, Hosny H, Afifi A, Nagy M, Mahgoub A, Simry W. Novel concepts and early results of repairing common arterial trunk. *Eur J Cardiothorac Surg*. (2021). ezab336. doi: 10.1093/ejcts/ezab336

24. Jacques Scherman, Peter Zilla. Poorly suited heart valve prostheses heighten the plight of patients with rheumatic heart disease. *J Cardiol*. (2020). 318:104–14 doi: 10.1016/j.jicard.2020.05.073

25. Hickey PA, Connor JA, Cherian KM, Jenkins K, Doherty K, Zhang H, et al. International quality improvement initiatives. *Cardiol Young*. (2017) 27:561–8. doi: 10.1017/S1047951117002633

26. Kotit S, Phillips DIW, Afifi A. and Yacoub M. The “Cairo Accord”-towards the eradication of RHD: an update. *Front Cardiovasc Med*. (2021) 8:690227. doi: 10.3389/fcvm.2021.690227

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer PP declared a shared affiliation, with one of the authors MY to the handling editor at the time of the review.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Afifi, Shehata, Nagi, Sultan and Yacoub. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.